Comprehensive Genomic Profiling of High-Risk Pediatric Cancer Patients Has a Measurable Impact on Clinical Care.

Saved in:
Bibliographic Details
Title: Comprehensive Genomic Profiling of High-Risk Pediatric Cancer Patients Has a Measurable Impact on Clinical Care.
Authors: Summers RJ; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta/Emory University, Atlanta, GA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA., Castellino SM; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta/Emory University, Atlanta, GA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA., Porter CC; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta/Emory University, Atlanta, GA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA., MacDonald TJ; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta/Emory University, Atlanta, GA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA., Basu GD; Exact Sciences, Phoenix, AZ., Szelinger S; Exact Sciences, Phoenix, AZ., Bhasin MK; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta/Emory University, Atlanta, GA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA.; Department of Biomedical Informatics, Emory University School of Medicine, Atlanta, GA., Cash T; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta/Emory University, Atlanta, GA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA., Carter AB; Department of Pathology and Laboratory Medicine, Children's Healthcare of Atlanta, Atlanta, GA., Castellino RC; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta/Emory University, Atlanta, GA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA., Fangusaro JR; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta/Emory University, Atlanta, GA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA., Mitchell SG; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta/Emory University, Atlanta, GA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA., Pauly MG; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta/Emory University, Atlanta, GA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA., Pencheva B; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta/Emory University, Atlanta, GA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA., Wechsler DS; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta/Emory University, Atlanta, GA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA., Graham DK; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta/Emory University, Atlanta, GA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA., Goldsmith KC; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta/Emory University, Atlanta, GA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA.
Source: JCO precision oncology [JCO Precis Oncol] 2022 Apr; Vol. 6, pp. e2100451.
Publication Type: Clinical Trial; Journal Article
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2473-4284
DOI:10.1200/PO.21.00451